The Food and Drug Administration today authorized state-licensed pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) to patients as a treatment for those at high risk of severe COVID-19. Because Paxlovid must be taken within five days of symptom onset, the change could spur expanded access and more-timely treatment of eligible patients. The change was made through an amended emergency use authorization. 

Related News Articles

Headline
Jurisdictions that have used 90% of their JYNNEOS monkeypox vaccine supply and are administering the vaccine intradermally to adults can begin ordering…
Headline
The Department of Health and Human Services Monday began accepting orders from states and other jurisdictions for a portion of 442,000 additional doses of the…
Headline
The Food and Drug Administration Friday said it does not recommend screening or testing blood donors for the monkeypox virus, given “the robustness” of…
Headline
The Food and Drug Administration yesterday advised people who get a negative result from an at-home COVID-19 antigen test to test themselves again after…
Headline
The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the…
Headline
The Centers for Disease Control and Prevention today released updated guidance to help people protect themselves and others if they are exposed to, sick or…